Why Dividend Investors Should Consider Eli Lilly

By most measures, Eli Lilly (LLY) stock looks cheap. It trades at a P/E ratio of 7.7. It yields 5.6%, more than three times the yield on the S&P 500. But like other pharmaceutical companies, it faces a patent cliff, in this case beginning this year. Its bestselling drug, Zyprexa, loses U.S. patent protection in October. At $5.0 billion in sales, Lilly will be hard pressed to replace this 22% of revenue. And unlike some... Read more

Older articles featuring LLY: